Correction to: Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice (BMC Pulmonary Medicine, (2010), 10, 1, (26), 10.1186/1471-2466-10-26);Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice

BMC Pulmonary Medicine

Volumn 10, Issue , 2010, Pages

  Udalov, Sergey ^a   Dumitrascu, Rio ^a   Pullamsetti, Soni S ^a,b   Al tamari, Hamza M ^a   Weissmann, Norbert ^a   Ghofrani, Hossein A ^a   Guenther, Andreas ^a   Voswinckel, Robert ^a,b   Seeger, Werner ^a,b   Grimminger, Friedrich ^a   Schermuly, Ralph T ^a,b  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CILOMILAST; COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA1; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHOSPHODIESTERASE IV; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARBOXYLIC ACID; COLLAGEN TYPE I, ALPHA 1 CHAIN; NITRILE; PHOSPHODIESTERASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG COMPLIANCE; LUNG FIBROSIS; LUNG LAVAGE; LYMPHOCYTE COUNT; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; OVERALL SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PNEUMONIA;

ANIMALS; BLEOMYCIN; CARBOXYLIC ACIDS; COLLAGEN TYPE I; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE MODELS, ANIMAL; INTERLEUKIN-1BETA; INTERLEUKIN-6; LUNG; MALE; MICE; MICE, INBRED C57BL; NITRILES; PHOSPHODIESTERASE INHIBITORS; PNEUMONIA; PULMONARY FIBROSIS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951793917     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-022-01876-5     Document Type: Erratum

References (39)

1. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008, 3:8. 10.1186/1750-1172-3-8, 2330030, 18366757.
2. Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993, 143:651-655. 1887194, 8362967.
3. Kline JN, Schwartz DA, Monick MM, Floerchinger CS, Hunninghake GW. Relative release of interleukin-1 beta and interleukin-1 receptor antagonist by alveolar macrophages. A study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis. Chest 1993, 104:47-53. 10.1378/chest.104.1.47, 8325116.
4. Takizawa H, Satoh M, Okazaki H, Matsuzaki G, Suzuki N, Ishii A, Suko M, Okudaira H, Morita Y, Ito K. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol 1997, 107:175-181. 10.1046/j.1365-2249.1997.d01-905.x, 1904552, 9010273.
5. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006, 173:769-776. 10.1164/rccm.200505-717OC, 16415276.
6. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109:366-398. 10.1016/j.pharmthera.2005.07.003, 16102838.
7. McLaughlin MM, Cieslinski LB, Burman M, Torphy TJ, Livi GP. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J Biol Chem 1993, 268:6470-6476.
8. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 1999, 56:170-174.
9. Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci 2004, 75:823-840. 10.1016/j.lfs.2004.01.021, 15183075.
10. Barnes AP, Livera G, Huang P, Sun C, O'Neal WK, Conti M, Stutts MJ, Milgram SL. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem 2005, 280:7997-8003. 10.1074/jbc.M407521200, 15611099.
11. Liu X, Ostrom RS, Insel PA. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol Cell Physiol 2004, 286:C1089-1099. 10.1152/ajpcell.00461.2003, 15075208.
12. Kohyama T, Liu X, Kim HJ, Kobayashi T, Ertl RF, Wen FQ, Takizawa H, Rennard SI. Prostacyclin analogs inhibit fibroblast migration. Am J Physiol Lung Cell Mol Physiol 2002, 283:L428-432.
13. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, Moore BB. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 2003, 29:537-544. 10.1165/rcmb.2002-0243OC, 12738687.
14. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson JA. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 1996, 118:649-658. 1909726, 8762090.
15. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 2002, 99:7628-7633. 10.1073/pnas.122041599, 124305, 12032334.
16. Rennard SI, Schachter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006, 129:56-66. 10.1378/chest.129.1.56, 16424413.
17. Pullamsetti S, Krick S, Yilmaz H, Ghofrani HA, Schudt C, Weissmann N, Fuchs B, Seeger W, Grimminger F, Schermuly RT. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 2005, 6:128. 10.1186/1465-9921-6-128, 1291406, 16262900.
18. Kohyama T, Liu X, Zhu YK, Wen FQ, Wang HJ, Fang Q, Kobayashi T, Rennard SI. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase. Am J Respir Cell Mol Biol 2002, 27:487-494.
19. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998, 287:705-711.
20. Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther 2006, 19:343-352. 10.1016/j.pupt.2005.09.002, 16257550.
21. Corbel M, Germain N, Lanchou J, Molet S, R e Silva PM, Martins MA, Boichot E, Lagente V. The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between tumor necrosis factor-alpha and interleukin-10. J Pharmacol Exp Ther 2002, 301:258-265. 10.1124/jpet.301.1.258, 11907182.
22. Videla S, Vilaseca J, Medina C, Mourelle M, Guarner F, Salas A, Malagelada JR. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. J Pharmacol Exp Ther 2006, 316:940-945. 10.1124/jpet.105.090837, 16254133.
23. Alejandre-Alcazar MA, Kwapiszewska G, Reiss I, Amarie OV, Marsh LM, Sevilla-Pérez J, Wygrecka M, Eul B, Köbrich S, Hesse M, Schermuly RT, Seeger W, Eickelberg O, Morty RE. Hyperoxia modulates TGF-beta/BMP signaling in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2007, 292:L537-549. 10.1152/ajplung.00050.2006, 17071723.
24. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988, 41:467-470. 10.1136/jcp.41.4.467, 1141479, 3366935.
25. Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 2005, 175:1523-1531.
26. Ma D, Wu P, Egan RW, Billah MM, Wang P. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol 1999, 55:50-57.
27. Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, Barnette MS. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999, 128:1393-1398. 10.1038/sj.bjp.0702911, 1571768, 10602317.
28. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, Mustelin T, Zaccolo M, Houslay M, Tasken K. TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 2004, 173:4847-4858.
29. Lesur OJ, Mancini NM, Humbert JC, Chabot F, Polu J-M. Interleukin-6, Interferon-gamma, and phospholipid levels in the alveolar lining fluid of human lungs: profiles in coal worker's pneumoconiosis and idiopathic pulmonary fibrosis. Chest 1994, 106:407-413. 10.1378/chest.106.2.407, 7774311.
30. Cailes JB, O'Connor C, Pantelidis P, Southcott AM, Fitzgerald MX, Black CM, du Bois RM. Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis. Eur Respir J 1996, 9:992-999. 10.1183/09031936.96.09050992, 8793462.
31. Obayashi Y, Yamadori I, Fujita J, Yoshinouchi T, Ueda N, Takahara J. The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest 1997, 112:1338-1343. 10.1378/chest.112.5.1338, 9367478.
32. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, Jin SL, Conti M. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 2004, 173:7531-7538.
33. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 2002, 83:111-119. 10.1046/j.1365-2613.2002.00220.x, 12383190.
34. Denis M. Interleukin-6 in mouse hypersensitivity pneumonitis: changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6. J Leukoc Biol 1992, 52:197-201.
35. Prabhakar U, Lipshutz D, Bartus JO, Slivjak MJ, Smith EF, Lee JC, Esser KM. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 1994, 16:805-816. 10.1016/0192-0561(94)90054-X, 7843852.
36. Losa Garcia JE, Rodriguez FM, Martin de Cabo MR, Garcia Salgado MJ, Losada JP, Villaron LG, Lopez AJ, Arellano JL. Evaluation of inflammatory cytokine secretion by human alveolar macrophages. Mediators Inflamm 1999, 8:43-51. 10.1080/09629359990711, 1781780, 10704089.
37. Battegay EJ, Raines EW, Colbert T, Ross R. TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol 1995, 154:6040-6047.
38. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994, 7:515-518. 10.1183/09031936.94.07030515, 7516893.
39. Dumaz N, Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. FEBS Journal 2005, 272:3491-3504. 10.1111/j.1742-4658.2005.04763.x, 16008550.